This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply. Data presented by Dr Williams support our recent observation that low-dose inhaled corticosteroids are effective in preventing ED visits for asthma.¹ Although neither Dr Williams' study nor ours evaluated lung function or patient symptoms, a recently conducted meta-analysis from Holt and colleagues² indicates that 80% of maximum benefits on lung function and symptoms occur at fluticasone-equivalent doses of 200 µg/d or less.² Doses greater than 500 µg/d do not appear to add any additional therapeutic benefit for patients.² On the other hand, risks of important systemic adverse effects including bone demineralization and cataracts increase in a dose-dependent fashion.^3-4 For these reasons, we agree with the NAEPP guidelines suggesting that clinicians use the "lowest possible dose of inhaled corticosteroid to maintain control" of asthma.⁵ Based on current evidence, for most patients, this can be achieved with total daily doses less than 500 µg of fluticasone (or equivalent).

Don D. . . . [Full Text of this Article]